DE10199068I2 - Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion. - Google Patents

Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.

Info

Publication number
DE10199068I2
DE10199068I2 DE2001199068 DE10199068C DE10199068I2 DE 10199068 I2 DE10199068 I2 DE 10199068I2 DE 2001199068 DE2001199068 DE 2001199068 DE 10199068 C DE10199068 C DE 10199068C DE 10199068 I2 DE10199068 I2 DE 10199068I2
Authority
DE
Germany
Prior art keywords
treatment
dosage forms
erectile dysfunction
forms containing
sublingual dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2001199068
Other languages
English (en)
Other versions
DE10199068I1 (de
Inventor
Ragab El-Rashidy
Jeremy Heaton
Alvaro Morales
Michael Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Pentech Pharmaceuticals Inc
Original Assignee
Queens University at Kingston
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10199068(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Queens University at Kingston, Pentech Pharmaceuticals Inc filed Critical Queens University at Kingston
Publication of DE10199068I1 publication Critical patent/DE10199068I1/de
Application granted granted Critical
Publication of DE10199068I2 publication Critical patent/DE10199068I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
DE2001199068 1994-04-22 1995-04-21 Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion. Active DE10199068I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22
PCT/US1995/004897 WO1995028930A1 (en) 1994-04-22 1995-04-21 Dosage forms and method for ameliorating male erectile dysfunction

Publications (2)

Publication Number Publication Date
DE10199068I1 DE10199068I1 (de) 2003-06-05
DE10199068I2 true DE10199068I2 (de) 2004-05-06

Family

ID=22868404

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69514794T Expired - Lifetime DE69514794T2 (de) 1994-04-22 1995-04-21 Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
DE69534693T Expired - Fee Related DE69534693T2 (de) 1994-04-22 1995-04-21 Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
DE2001199068 Active DE10199068I2 (de) 1994-04-22 1995-04-21 Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69514794T Expired - Lifetime DE69514794T2 (de) 1994-04-22 1995-04-21 Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
DE69534693T Expired - Fee Related DE69534693T2 (de) 1994-04-22 1995-04-21 Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz

Country Status (16)

Country Link
US (3) US5770606A (de)
EP (2) EP0758895B1 (de)
JP (1) JP3310982B2 (de)
KR (1) KR100374924B1 (de)
AT (2) ATE189121T1 (de)
AU (1) AU703608B2 (de)
CA (1) CA2188385C (de)
DE (3) DE69514794T2 (de)
DK (2) DK0978282T3 (de)
ES (2) ES2143049T3 (de)
GR (1) GR3033084T3 (de)
HK (2) HK1025742A1 (de)
LU (1) LU90856I2 (de)
NL (1) NL300072I1 (de)
PT (1) PT758895E (de)
WO (1) WO1995028930A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (de) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmische Zubereitung zur Behandlung von Kurzsichtigkeit enthaltend einen Dopaminagonisten und Cyclodextrin
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
ATE333279T1 (de) * 1997-05-19 2006-08-15 Zonagen Inc Kombinationstherapie zur modulation der humanen sexualreaktion
BR9809508A (pt) * 1997-05-29 2000-06-20 Mochida Pharm Co Ltd Agente terapêutico para disfunção de ereção
EP1005336A4 (de) 1997-07-09 2001-01-17 Androsolutions Inc Verbesserte verfahren und zusammensetzungen zur behandlung männlicher erektionsstörungen
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6284763B1 (en) 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
EE05315B1 (et) 1999-09-03 2010-08-16 Eli Lilly And Company Dapoksetiini v?i selle farmatseutiliselt vastuv?etava soola kasutamine ravimi valmistamiseks, mis on ette n„htud imetajal esineva seksuaalse funktsioonih„ire ravimiseks v?i m?jutamiseks
EP1284735A4 (de) * 2000-04-07 2006-01-11 Tap Pharmaceutical Prod Inc APOMORPHINDERIVATE UND METHODEN FüR DEREN VERWENDUNG
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6852323B2 (en) * 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CN1486183A (zh) 2000-11-15 2004-03-31 ����ҽҩƷ���޹�˾ 使用阿朴吗啡治疗抗抑郁药引发的性功能障碍
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (de) * 2001-01-19 2002-07-24 Sanofi-Synthelabo Neue Kombination mit Alfuzosin und Apomorphin als Aktiva
US20030022912A1 (en) * 2001-02-08 2003-01-30 Martino Alice C. Rapid-onset medicament for treatment of sexual dysfunction
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
US20030235617A1 (en) * 2002-02-07 2003-12-25 Martino Alice C. Pharmaceutical dosage form for mucosal delivery
US20060004190A1 (en) * 2002-03-19 2006-01-05 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
EP1509182A4 (de) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc Implantierbare polymere vorrichtung zur verzögerten freisetzung von buprenorphin
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
DK1610791T3 (da) 2003-03-31 2011-05-09 Titan Pharmaceuticals Inc Implanterbar polymer anordning for vedvarende frigivelse af dopamin-agonist
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
ME00320B (me) * 2003-06-17 2011-05-10 Janssen Pharmaceutica Nv Supstituisani spirobenzazepini
DK1937276T3 (da) 2005-10-12 2013-02-11 Besins Healthcare Luxembourg Forbedret testosterongel og fremgangsmåde til anvendelse deraf
WO2007084591A2 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
ES2554626T3 (es) 2009-06-12 2015-12-22 Cynapsus Therapeutics Inc. Apomorfina sublingual
ES2791715T3 (es) 2010-12-16 2020-11-05 Sunovion Pharmaceuticals Inc Películas sublinguales
EP3524247A1 (de) * 2013-11-11 2019-08-14 Impax Laboratories, Inc. Schnell zerfallende formulierungen und verfahren zur verwendung
JP6632999B2 (ja) * 2014-06-12 2020-01-22 ユニバーシティ オブ ノートルダム デュ ラック 神経疾患および大脳損傷の処置のための組成物および方法
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
DK0865789T3 (da) * 1993-03-26 2005-07-18 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af dihydroergotamin

Also Published As

Publication number Publication date
HK1025742A1 (en) 2000-11-24
CA2188385A1 (en) 1995-11-02
EP0758895A1 (de) 1997-02-26
EP0758895A4 (de) 1997-04-09
EP0978282B1 (de) 2005-12-14
WO1995028930A1 (en) 1995-11-02
ATE312609T1 (de) 2005-12-15
ATE189121T1 (de) 2000-02-15
JPH09512273A (ja) 1997-12-09
HK1014239A1 (en) 1999-09-24
EP0978282A2 (de) 2000-02-09
EP0758895B1 (de) 2000-01-26
ES2143049T3 (es) 2000-05-01
PT758895E (pt) 2000-05-31
KR100374924B1 (ko) 2003-07-22
DK0758895T3 (da) 2000-06-13
DE69534693T2 (de) 2006-08-31
KR970702041A (ko) 1997-05-13
DE10199068I1 (de) 2003-06-05
US5770606A (en) 1998-06-23
LU90856I2 (fr) 2002-01-24
US5985889A (en) 1999-11-16
US6200983B1 (en) 2001-03-13
DE69514794T2 (de) 2000-07-27
AU703608B2 (en) 1999-03-25
AU2295895A (en) 1995-11-16
ES2256999T3 (es) 2006-07-16
GR3033084T3 (en) 2000-08-31
DE69514794D1 (de) 2000-03-02
DK0978282T3 (da) 2006-04-10
JP3310982B2 (ja) 2002-08-05
DE69534693D1 (de) 2006-01-19
EP0978282A3 (de) 2000-06-07
NL300072I1 (nl) 2002-02-01
CA2188385C (en) 2000-07-11

Similar Documents

Publication Publication Date Title
DE10199068I1 (de) Sublinguale Dosierungsformen enthaltend Apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
MX171177B (es) Composicion para desinfectar sustratos
ATE192151T1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
NO903148L (no) Hemoreguleringspeptider.
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE69302799T2 (de) Zusammensetzung für die Behandlung von Kesselwasser
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.
DE3762526D1 (de) Hochkonzentrierte saeurezusammensetzungen fuer die behandlung von wasser und die reinigung von anlagen.
DE69504717D1 (de) Behandlung von organischen Verbindungen zur Reduzierung des Chlorgehaltes
ATE81972T1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
KR950700685A (ko) 최음제로서 사용되는 요드화수소산(use of hydriodic acid as an aphrodisiac)
DE69214647T2 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
DE69103294D1 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
TR200000266T2 (tr) Antimetastaz maddeler olarak faydalı oligo-tiofenler, bunların ve bunları ihtiva eden farmasötik bileşimlerin hazırlanması.
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции
ATE225664T1 (de) Verwendung von humanem alpha 1-sauren glycoprotein zur herstellung einer pharmazeutischen präparation
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate
ATE64683T1 (de) Zusammensetzung zur behandlung von haemorroiden.
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
SU1533391A1 (ru) Состав для обработки призабойной зоны скважины